| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| DORDAVIPRONE
| DORDAVIPRONE | ANTINEOPLASTIC | ORAL | Cmax 7.2 MICROMOLAR Tmax 1.4 HOUR VD 450 LITER PPB 96 PERCENT Cl 27 LITER / HOUR HT 11 HOUR SOLUBILITY FREELY SOLUBLE IN WATER | MITOCHONDRIAL CASEINOLYTIC PROTEASE P (CLPP) DOPAMINE D2 RECEPTOR | - more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| SUNVOZERTINIB
| SUNVOZERTINIB | ANTINEOPLASTIC | ORAL | Cmax 705 NANOMOLAR Tmax 6 HOUR VD 2116 LITER PPB 91 PERCENT Cl 29 LITER / HOUR HT 50 HOUR | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) | - more at DrugCentral | EMA | |||
